Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 20 | 2024 | 78 | 4.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 16 | 2024 | 742 | 3.230 |
Why?
|
| Prediabetic State | 6 | 2024 | 50 | 2.840 |
Why?
|
| Postmenopause | 24 | 2022 | 266 | 2.730 |
Why?
|
| Weight Loss | 7 | 2020 | 296 | 1.990 |
Why?
|
| Women's Health | 20 | 2023 | 208 | 1.940 |
Why?
|
| Obesity | 12 | 2023 | 839 | 1.670 |
Why?
|
| Humans | 92 | 2024 | 18058 | 1.630 |
Why?
|
| Cholecalciferol | 9 | 2019 | 15 | 1.610 |
Why?
|
| Accidental Falls | 4 | 2015 | 42 | 1.560 |
Why?
|
| Female | 78 | 2023 | 12838 | 1.520 |
Why?
|
| Menopause | 6 | 2020 | 72 | 1.480 |
Why?
|
| Aged | 58 | 2020 | 6258 | 1.440 |
Why?
|
| Fractures, Bone | 7 | 2022 | 91 | 1.410 |
Why?
|
| Vitamins | 7 | 2024 | 66 | 1.360 |
Why?
|
| Dietary Supplements | 13 | 2020 | 91 | 1.330 |
Why?
|
| Mass Screening | 4 | 2022 | 678 | 1.280 |
Why?
|
| Vitamin D Deficiency | 4 | 2015 | 21 | 1.250 |
Why?
|
| Hypoglycemic Agents | 3 | 2022 | 289 | 1.240 |
Why?
|
| Calcium Carbonate | 6 | 2019 | 9 | 1.180 |
Why?
|
| Prenatal Care | 2 | 2020 | 136 | 1.160 |
Why?
|
| Cognition | 6 | 2013 | 80 | 1.120 |
Why?
|
| Risk Factors | 39 | 2023 | 3394 | 1.110 |
Why?
|
| Osteoporotic Fractures | 6 | 2017 | 41 | 1.060 |
Why?
|
| Exercise Therapy | 3 | 2015 | 70 | 1.020 |
Why?
|
| Middle Aged | 47 | 2021 | 8073 | 1.020 |
Why?
|
| Calcium, Dietary | 5 | 2017 | 30 | 1.010 |
Why?
|
| Behavior Therapy | 4 | 2021 | 152 | 1.010 |
Why?
|
| Prospective Studies | 23 | 2023 | 1294 | 0.960 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2017 | 105 | 0.960 |
Why?
|
| Metformin | 2 | 2022 | 60 | 0.960 |
Why?
|
| Aging | 4 | 2015 | 159 | 0.900 |
Why?
|
| Hip Fractures | 6 | 2016 | 70 | 0.880 |
Why?
|
| Testosterone | 3 | 2014 | 22 | 0.880 |
Why?
|
| Estradiol | 4 | 2014 | 24 | 0.860 |
Why?
|
| Calcium | 6 | 2020 | 34 | 0.850 |
Why?
|
| Hot Flashes | 6 | 2020 | 39 | 0.840 |
Why?
|
| Estrogens | 5 | 2022 | 73 | 0.830 |
Why?
|
| Dementia | 3 | 2020 | 103 | 0.820 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 231 | 0.790 |
Why?
|
| Weight Gain | 6 | 2020 | 180 | 0.770 |
Why?
|
| Health Behavior | 5 | 2021 | 379 | 0.770 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 18 | 0.750 |
Why?
|
| Aged, 80 and over | 17 | 2019 | 1956 | 0.730 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2016 | 23 | 0.700 |
Why?
|
| Incidence | 14 | 2019 | 1297 | 0.680 |
Why?
|
| Preconception Care | 2 | 2016 | 45 | 0.680 |
Why?
|
| Cognitive Dysfunction | 2 | 2016 | 46 | 0.670 |
Why?
|
| Breast Density | 4 | 2022 | 31 | 0.660 |
Why?
|
| Obesity Management | 1 | 2018 | 4 | 0.660 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 193 | 0.630 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2016 | 33 | 0.610 |
Why?
|
| Body Mass Index | 15 | 2023 | 961 | 0.610 |
Why?
|
| Cohort Studies | 16 | 2020 | 2631 | 0.600 |
Why?
|
| Demography | 1 | 2017 | 106 | 0.600 |
Why?
|
| Femoral Fractures | 1 | 2017 | 22 | 0.590 |
Why?
|
| Menstruation | 1 | 2017 | 8 | 0.580 |
Why?
|
| Follow-Up Studies | 15 | 2023 | 1255 | 0.580 |
Why?
|
| United States | 22 | 2019 | 4119 | 0.580 |
Why?
|
| Primary Health Care | 2 | 2015 | 843 | 0.580 |
Why?
|
| Reproductive History | 1 | 2017 | 19 | 0.580 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 55 | 0.580 |
Why?
|
| Adult | 19 | 2022 | 7696 | 0.560 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1309 | 0.550 |
Why?
|
| Breast | 4 | 2019 | 85 | 0.540 |
Why?
|
| Blood Glucose | 5 | 2024 | 344 | 0.540 |
Why?
|
| Residence Characteristics | 2 | 2017 | 248 | 0.530 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 55 | 0.530 |
Why?
|
| Treatment Outcome | 10 | 2021 | 1259 | 0.520 |
Why?
|
| Diet | 4 | 2021 | 359 | 0.500 |
Why?
|
| Male | 16 | 2020 | 10173 | 0.480 |
Why?
|
| Body Composition | 3 | 2023 | 80 | 0.480 |
Why?
|
| Time Factors | 9 | 2019 | 1114 | 0.480 |
Why?
|
| Diphosphonates | 1 | 2014 | 64 | 0.470 |
Why?
|
| Double-Blind Method | 9 | 2019 | 160 | 0.460 |
Why?
|
| Macular Degeneration | 4 | 2015 | 18 | 0.460 |
Why?
|
| Drug Compounding | 1 | 2013 | 3 | 0.450 |
Why?
|
| Nonprescription Drugs | 1 | 2013 | 6 | 0.450 |
Why?
|
| Bone Density | 6 | 2019 | 98 | 0.450 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 1023 | 0.430 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 745 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 328 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 407 | 0.370 |
Why?
|
| Spinal Fractures | 3 | 2016 | 12 | 0.370 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 1346 | 0.360 |
Why?
|
| Health Status Disparities | 1 | 2011 | 154 | 0.360 |
Why?
|
| Overweight | 4 | 2016 | 272 | 0.350 |
Why?
|
| Pregnancy | 7 | 2021 | 1484 | 0.350 |
Why?
|
| Adolescent | 8 | 2022 | 3714 | 0.340 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2019 | 42 | 0.340 |
Why?
|
| Sleep | 2 | 2019 | 56 | 0.340 |
Why?
|
| Preventive Health Services | 2 | 2022 | 164 | 0.330 |
Why?
|
| Body Weight | 3 | 2020 | 216 | 0.330 |
Why?
|
| Menarche | 2 | 2019 | 30 | 0.320 |
Why?
|
| Sweating | 3 | 2017 | 9 | 0.300 |
Why?
|
| Exercise | 3 | 2021 | 478 | 0.300 |
Why?
|
| Child | 7 | 2023 | 2519 | 0.290 |
Why?
|
| Neoplasms | 4 | 2016 | 464 | 0.280 |
Why?
|
| Life Style | 3 | 2015 | 329 | 0.280 |
Why?
|
| Fetal Macrosomia | 3 | 2021 | 27 | 0.270 |
Why?
|
| Age Factors | 5 | 2016 | 945 | 0.270 |
Why?
|
| Adiposity | 2 | 2023 | 66 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 103 | 0.260 |
Why?
|
| Self Report | 5 | 2019 | 252 | 0.260 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 147 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2017 | 1137 | 0.260 |
Why?
|
| Emotions | 2 | 2015 | 33 | 0.250 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 613 | 0.250 |
Why?
|
| Fatigue | 2 | 2015 | 35 | 0.250 |
Why?
|
| Sleep Wake Disorders | 2 | 2015 | 40 | 0.250 |
Why?
|
| Diet, Reducing | 3 | 2015 | 25 | 0.240 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 37 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2017 | 2498 | 0.230 |
Why?
|
| Carotenoids | 2 | 2014 | 30 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2016 | 303 | 0.230 |
Why?
|
| Body Size | 2 | 2020 | 31 | 0.220 |
Why?
|
| Young Adult | 5 | 2022 | 2479 | 0.210 |
Why?
|
| Osteoporosis | 2 | 2014 | 87 | 0.210 |
Why?
|
| Advisory Committees | 1 | 2022 | 111 | 0.200 |
Why?
|
| Premature Birth | 1 | 2023 | 135 | 0.200 |
Why?
|
| Geriatric Assessment | 2 | 2012 | 36 | 0.190 |
Why?
|
| Odds Ratio | 8 | 2017 | 692 | 0.190 |
Why?
|
| Pregnancy Trimesters | 1 | 2020 | 29 | 0.180 |
Why?
|
| Glycemic Load | 1 | 2020 | 1 | 0.180 |
Why?
|
| Glycemic Index | 1 | 2020 | 21 | 0.180 |
Why?
|
| Sexual Maturation | 1 | 2019 | 7 | 0.180 |
Why?
|
| Anthropometry | 1 | 2020 | 63 | 0.180 |
Why?
|
| Adipose Tissue | 2 | 2018 | 59 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 526 | 0.180 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 97 | 0.180 |
Why?
|
| Contraceptives, Oral | 1 | 1999 | 25 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 40 | 0.170 |
Why?
|
| Parity | 1 | 2019 | 75 | 0.170 |
Why?
|
| Counseling | 1 | 2021 | 199 | 0.170 |
Why?
|
| Hispanic Americans | 3 | 2021 | 431 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 158 | 0.170 |
Why?
|
| Puberty | 1 | 2019 | 58 | 0.170 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 124 | 0.170 |
Why?
|
| Logistic Models | 3 | 2016 | 953 | 0.160 |
Why?
|
| Dietary Fats | 2 | 2016 | 90 | 0.160 |
Why?
|
| Bias | 1 | 2018 | 109 | 0.160 |
Why?
|
| Health Promotion | 1 | 2021 | 295 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2019 | 134 | 0.150 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 16 | 0.150 |
Why?
|
| European Continental Ancestry Group | 3 | 2017 | 559 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2017 | 9 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2016 | 165 | 0.150 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 13 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2017 | 30 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 45 | 0.150 |
Why?
|
| Biomarkers | 2 | 2015 | 306 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 39 | 0.140 |
Why?
|
| Calcifediol | 2 | 2014 | 3 | 0.140 |
Why?
|
| Body Height | 2 | 2018 | 59 | 0.140 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2016 | 2 | 0.140 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 5 | 0.140 |
Why?
|
| Reproduction | 1 | 2016 | 12 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2015 | 6 | 0.140 |
Why?
|
| Complement Factor I | 1 | 2015 | 1 | 0.140 |
Why?
|
| Cause of Death | 2 | 2019 | 181 | 0.130 |
Why?
|
| Age of Onset | 1 | 2015 | 82 | 0.130 |
Why?
|
| Institutionalization | 1 | 2015 | 1 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 667 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2015 | 6 | 0.130 |
Why?
|
| Vasomotor System | 1 | 2014 | 5 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 144 | 0.130 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 29 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 132 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 7 | 0.130 |
Why?
|
| African Americans | 2 | 2017 | 485 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 734 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 705 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 67 | 0.120 |
Why?
|
| Insulin | 1 | 2015 | 208 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 57 | 0.120 |
Why?
|
| Oregon | 1 | 2014 | 195 | 0.120 |
Why?
|
| Risk | 2 | 2009 | 552 | 0.120 |
Why?
|
| Mortality | 1 | 2015 | 121 | 0.120 |
Why?
|
| Hand Strength | 1 | 2013 | 11 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 78 | 0.120 |
Why?
|
| Memory | 1 | 2013 | 12 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 164 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 177 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2015 | 179 | 0.120 |
Why?
|
| Washington | 1 | 2014 | 384 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2012 | 31 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 178 | 0.110 |
Why?
|
| Retinal Pigments | 1 | 2013 | 3 | 0.110 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 2 | 0.110 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.110 |
Why?
|
| Asian Americans | 1 | 2014 | 184 | 0.110 |
Why?
|
| Walking | 1 | 2013 | 87 | 0.110 |
Why?
|
| Research Design | 2 | 2011 | 393 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Thyroxine | 1 | 2012 | 5 | 0.100 |
Why?
|
| Thyroid Gland | 1 | 2012 | 5 | 0.100 |
Why?
|
| Thyrotropin | 1 | 2012 | 8 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 445 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2023 | 852 | 0.100 |
Why?
|
| Lactones | 1 | 2011 | 12 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 10 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 15 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2011 | 23 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 255 | 0.100 |
Why?
|
| Models, Biological | 1 | 2011 | 32 | 0.100 |
Why?
|
| Prevalence | 4 | 2016 | 892 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2023 | 59 | 0.100 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 338 | 0.100 |
Why?
|
| Melanoma | 1 | 2011 | 37 | 0.100 |
Why?
|
| Survival Rate | 1 | 2011 | 266 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 162 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 112 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 64 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 195 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 118 | 0.090 |
Why?
|
| Mammography | 2 | 2022 | 173 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2020 | 81 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1164 | 0.080 |
Why?
|
| Depression | 1 | 2012 | 512 | 0.070 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Stroke | 2 | 2019 | 306 | 0.070 |
Why?
|
| Phenotype | 2 | 2019 | 145 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 127 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 643 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 454 | 0.060 |
Why?
|
| Genotype | 2 | 2015 | 251 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 595 | 0.060 |
Why?
|
| Prognosis | 2 | 2011 | 619 | 0.060 |
Why?
|
| Maternal Age | 1 | 2021 | 79 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2021 | 29 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2001 | 69 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 41 | 0.050 |
Why?
|
| Dementia, Vascular | 1 | 2020 | 5 | 0.050 |
Why?
|
| Fasting | 1 | 2020 | 47 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 37 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 106 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 29 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2020 | 66 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 20 | 0.040 |
Why?
|
| Hip Joint | 1 | 2019 | 4 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 5 | 0.040 |
Why?
|
| Actigraphy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2021 | 109 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 36 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 57 | 0.040 |
Why?
|
| Biopsy | 1 | 1999 | 73 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 86 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 1999 | 330 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 251 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 6 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 6 | 0.040 |
Why?
|
| Metabolomics | 1 | 2017 | 8 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2017 | 32 | 0.040 |
Why?
|
| Intention | 1 | 2017 | 28 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2017 | 60 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 48 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 19 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 30 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement Factor B | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement Factor H | 1 | 2015 | 1 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 49 | 0.030 |
Why?
|
| Proteins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 248 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2015 | 5 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 156 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 2 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 27 | 0.030 |
Why?
|
| Fetal Development | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cholesterol | 1 | 2014 | 112 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 80 | 0.030 |
Why?
|
| beta-Carotene 15,15'-Monooxygenase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2013 | 1 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 280 | 0.030 |
Why?
|
| Urinary Calculi | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 34 | 0.030 |
Why?
|
| Sunlight | 1 | 2012 | 16 | 0.030 |
Why?
|
| Edible Grain | 1 | 2012 | 14 | 0.030 |
Why?
|
| Seasons | 1 | 2012 | 99 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 618 | 0.030 |
Why?
|
| Fruit | 1 | 2012 | 72 | 0.030 |
Why?
|
| Vegetables | 1 | 2012 | 80 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 3 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2011 | 10 | 0.030 |
Why?
|
| Organ Size | 1 | 2011 | 16 | 0.030 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 97 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2015 | 504 | 0.020 |
Why?
|
| Zeaxanthins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Tocopherols | 1 | 2010 | 5 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2010 | 6 | 0.020 |
Why?
|
| Lutein | 1 | 2010 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 11 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 57 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 208 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 1 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 317 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 250 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 184 | 0.020 |
Why?
|
Concepts
(306)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->